Wegovy before and after 6 months: what the evidence actually shows

What STEP 1 data shows at the six-month point

The STEP 1 trial is the closest thing we have to a controlled, large-scale picture of how semaglutide 2.4mg changes body weight over time. Participants did not reach their maintenance dose immediately, titration ran through 0.25mg, 0.5mg, 1.0mg and 1.7mg over roughly 16 weeks before settling at 2.4mg. That means six months in, most participants had been on their maintenance dose for only a matter of weeks. Despite that, published analyses show cumulative weight reduction in the region of 10–12% by approximately week 24–28. The curve continued climbing after that, which is why the full 68-week average reached around 15%.

Those numbers matter for setting expectations. If your own progress looks slower than the headline 15% figure at six months, that is not a sign something has gone wrong, the full result takes the entire treatment course to develop. The NHS semaglutide medicines page explains the general mechanism and what the medicine is designed to do alongside reduced-calorie eating and increased activity.

It is also worth knowing that STEP 1 used a single dose ceiling of 2.4mg. The MHRA has since approved a higher 7.2mg maintenance dose, including a dedicated single-dose pen, which in its own trials produced around 20.7% average weight loss over 72 weeks. For people starting Wegovy now, the ceiling has shifted, and six-month results on the path to 7.2mg may look different again.

Why the six-month checkpoint matters clinically

Six months is not just a milestone people mark on a calendar. It is baked into clinical guidance. NICE's appraisal of semaglutide for weight management (TA875) states that treatment should be reviewed if weight loss is less than 5% after six months at the maintenance dose. That threshold exists to make sure continued prescribing is genuinely benefiting the person taking it, rather than running on optimism alone.

This is one reason the clinical review that happens before every repeat order at a regulated UK pharmacy matters more than it might seem at first. A prescriber looking at your six-month weight data is doing exactly what NICE describes: checking that the medicine is working for you specifically, at the dose you have reached. If it is, the case for continuing is strong. If progress has stalled well below 5%, that is a conversation to have with your prescriber about whether the dose, the support, or the approach needs to change.

People sometimes feel a quiet anxiety at six months, especially if they expected faster results or if friends seem to be responding differently. That is completely understandable. Biology varies. Dose timing, the presence of other health conditions and how appetite suppression plays out in daily life all shift the trajectory. A slower six-month result does not predict the final outcome. If you are finding it hard to read your own progress, our page on how long Wegovy takes to work walks through the timeline in more detail, including what to watch for in the early weeks.

What the dose trajectory looks like over six months

Understanding the dose schedule makes the six-month picture easier to interpret. Wegovy starts at 0.25mg weekly, stepping up roughly every four weeks: 0.5mg, then 1.0mg, then 1.7mg, then 2.4mg as the standard maintenance dose. That titration takes about 16 weeks. So at the six-month mark, a person who started on schedule has been at 2.4mg for around six to eight weeks, and the most significant appetite suppression and weight loss effects tend to build once the maintenance dose is sustained, not during the escalation phase.

People who experience more side effects during titration sometimes pause at an intermediate dose for a few extra weeks, which can push the maintenance phase later and compress what is achieved by month six. That is clinically sensible (tolerability matters) but it does shift the six-month snapshot, and if you want a clearer sense of what physical changes tend to look like around the three-month point, our page on Wegovy before and after three months gives a useful frame of reference for how results build through the middle of the titration period. For those further along who are curious about the changes that typically emerge a little later, our page covering Wegovy before and after four months shows what tends to become visible once the maintenance dose has had more time to take effect.

For context on how costs fit into the overall picture of private treatment, our cost context page covers what a legitimate UK price includes and why clinical review at every repeat matters for safety, not just paperwork. Wegovy is a prescription-only medicine; a prescriber assesses suitability and reviews progress before every supply.

The wider picture: what influences your six-month result

Trial averages are population figures. The individuals inside them range from people who lost very little to people who lost substantially more than 15%. Starting BMI, baseline metabolic health, adherence to the dose schedule, dietary changes made alongside the medicine, and how much movement becomes possible as weight falls, all of these pull results in different directions.

For a broader look at how Wegovy works, including eligibility and what the full treatment course involves, our main Wegovy page covers the licensed indication, the clinical evidence and how a private prescription route compares to NHS access. Some people also find it useful to read about earlier results at two months alongside the six-month data, since the contrast shows how much of the total reduction happens in the second half of treatment.

If you are considering starting or have questions about whether Wegovy is the right fit for your circumstances, a prescriber is the right person to work through that with you. You can start a free consultation with our clinical team at any point, no waiting list, and a real prescriber reviews your details the same day you submit them.

Start your free consultation and speak to our prescribers about whether Wegovy suits your situation.